Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

• CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidate
• Centauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026
• CARB-X’s additional funding brings their financial support to date for the Alphamer platform and lead compound non-clinical development to $12.3M

Alderley Park, Cheshire, UK, 29 July 2025: Centauri Therapeutics Limited (‘Centauri’ or ‘the Company’), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1M in funding for the development of their lead compound. The funds will contribute to the advancement of the lead candidate in Centauri’s ABX-01 programme into first in human clinical studies, and this latest funding brings CARB-X’s total support from 2019 to date to $12.3M.

Centauri announced the selection of its first clinical candidate in the ABX-01 programme in March 2025. The candidate is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. Based on the Company’s proprietary Alphamer® platform, it is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Early efficacy studies have demonstrated the compound’s activity against Gram-negative bacteria.

“The unwavering scientific and financial support from CARB-X has provided stability to Centauri as a company, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 programme from discovery, through early development, and is now providing a smooth and continuous path towards First in Human clinical studies,” said Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics. “We are thankful for CARB-X and their continued engagement and confidence, which has allowed us to move a step closer to delivering a much needed therapeutic for serious, drug-resistant Gram-negative infections, even in the most clinically vulnerable patients.”

Dr. Erin Duffy, Chief of Research and Development, CARB-X, commented: “We have been proud to support Centauri, beginning with answering key questions on the approach and continuing with the drug discovery that has led to the lead asset of ABX-01 and its progression towards building a dossier to support its advancement into first in human clinical trials.”

Full PR available here